- TgF344-AD - ALZFORUM
TgF344-AD rats express human APP with the Swedish mutation and human PSEN1 with the Δ exon 9 mutation Both transgenes are driven by the mouse prion promoter (Cohen et al , 2013) Compared with levels of the endogenous rat proteins, TgF344-AD rats express 2 6 times more human APP and 6 2 times more
- Semaglutide - ALZFORUM
Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is is a daily pill
- Alzheimers Association International Conference (AAIC) 2024
The Alzheimer’s Association International Conference, held July 28 to August 1, drew 8,200 attendees to the beautiful if distressed city of Philadelphia Thousands more watched online The growth reflects expansion in both research topics and commercialization ranging from drugs to mobile testing apps to head-only desktop MRI scanners The big news? Blood tests are getting really good
- Do Two APOE4 Alleles Always Mean Alzheimers? - ALZFORUM
For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold Now, scientists argue that people with two APOE4 alleles are not merely at risk, but are destined to develop AD As reported in Nature Medicine on May 6
- Semaglutide Attenuates Anxious and Depressive-Like Behaviors and . . .
Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis
- DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α . . .
Zhang L, Li C, Zhang Z, Zhang Z, Jin QQ, Li L, Hölscher C DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model
- Bile Acid: An Elixir of Youth? | ALZFORUM
Some scientists have suggested that GLP-1 receptor agonists such as semaglutide might slow aging (e g , Ortiz and de Freitas, 2024) Seeing GLP-1 appear in this context adds support to such claims, said Marc Tatar of Brown University in Providence, Rhode Island, who was not involved in the work
- Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction . . .
Rubin R Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions? JAMA 2024 May 14;331 (18):1519-1521 PubMed
|